Drugs / Nadroparine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT06845423 | May 2025 → May 2028 expected | venous thromboembolism | University Hospital, Brest | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT04536272 Comparator | Oct 2020 → Mar 2025 | heart failure, hemorrhagic disease, respiratory failure, thrombotic disease | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 3 | NCT00421538 Comparator | Jan 2008 → May 2015 | venous thromboembolism | University Hospital, Geneva | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nadroparine | “Nadroparine 2850 UI” NCT06845423 ↗ |
| Known as | nadroparine calcium | “Once-daily injection of 171 U/Kg/day of nadroparine calcium for 6 weeks.” NCT00421538 ↗ |
| Modality | Other / unclassified | “low-molecular-weight heparin nadroparin” PMID 27836513 ↗ Nov 2016 |
| Route | Subcutaneous | “nadroparin (171 UI/kg, subcutaneously, once a day)” PMID 27836513 ↗ Nov 2016 |